Carna Biosciences's Total Assets for the quarter that ended in Dec. 2025 was 円1,229.6 Mil.
During the past 12 months, Carna Biosciences's average Total Assets Growth Rate was 7.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -7.00% per year.
During the past 5 years, the average Total Assets Growth Rate was -2.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 8.70% per year.
During the past 13 years, Carna Biosciences's highest 3-Year average Total Assets Growth Rate was 57.30%. The lowest was -25.70%. And the median was 4.40%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Carna Biosciences's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Carna Biosciences Total Assets Related Terms
Carna Biosciences Total Assets Historical Data
* Premium members only.
The historical data trend for Carna Biosciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Carna Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carna Biosciences (TSE:4572) has a Total Assets of 円1,229.6 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' Total Assets too high?
Carna Biosciences' current Total Assets is 円1,229.6 Mil. Overall, Carna Biosciences has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Total Assets compare to VRTX and REGN?
Carna Biosciences' Total Assets of 円1,229.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current Total Assets is 円1,229.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円188.38, compared to a current price of 円348.00 — trading 84.7% above its estimated fair value. The current Total Assets is 円1,229.6 Mil. Carna Biosciences' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Total Assets is 円1,229.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carna Biosciences (TSE:4572) Overvalued in 2026?
Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued.
The current stock price of 円348.00 is trading 84.7% above its estimated GF Value™ of 円188.38.
GuruFocus considers Carna Biosciences to be Significantly Overvalued.
Key valuation signals for TSE:4572:
Total Assets: 円1,229.6 Mil
GF Value™: 円188.38 vs. price of 円348.00 (84.7% above fair value)
No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
34GF Score
Get the complete analysis for TSE:4572
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4572 has been successfully added to your 
